0
0
Published: June 15, 2026
CHICAGO — A common antiviral medication long prescribed to shorten the duration of seasonal influenza may have an unexpected second act: protecting the brain from cognitive decline.
In a study published June 5, 2026, in the peer-reviewed Cell Press journal Med, researchers at Northwestern University’s Feinberg School of Medicine discovered that the flu drug Tamiflu (oseltamivir) could help preserve memory and reduce chronic inflammation. While the preclinical research specifically looked at cognitive impairment in people living with HIV, scientists say the findings uncover a fundamental aging mechanism that could eventually change how doctors treat a wide array of age-related brain disorders, including dementia.
The Hidden Culprit: “Calming” Sugars and Brain Inflammation
Despite the life-saving success of modern antiretroviral therapy (ART) in suppressing the HIV virus, at least 25% of people living with HIV continue to develop memory, concentration, and cognitive problems. For years, the underlying driver of this persistent cognitive decline remained an elusive medical mystery.
The Northwestern research team approached the problem by analyzing blood samples from more than 100 participants living with HIV, split into cohorts with and without cognitive impairment. They discovered a clear biological pattern: patients suffering from memory deficits had a severe shortage of complex sugar molecules, known as glycans, bound to their blood proteins.
Specifically, the researchers traced the impairment to the loss of sialic acid—a crucial “calming” sugar molecule that naturally acts as a brake on the immune system, preventing it from overreacting.
As humans age, these anti-inflammatory, protective sugars naturally thin out, while pro-inflammatory sugars accumulate. This biological shift contributes to inflammaging—a state of chronic, low-grade inflammation that gradually damages tissues throughout the body, particularly in the brain. The study revealed that the more severe the loss of these calming sugars, the lower the patients scored on standard cognitive tests.
A Striking Sex-Specific Shift Around Menopause
One of the study’s most significant findings is how this sugar loss varies by biological sex. While glycan degradation occurs at a gradual, steady pace in men as they age, the pattern in women is non-linear and sharply accelerated by hormonal transitions.
MALE GLYCAN LOSS: [Steady, gradual decline across the lifespan]
FEMALE GLYCAN LOSS: [Slower initial loss] ----(Menopause Transition)----> [Rapid, accelerated decline]
“Before menopause, women show slower loss of anti-inflammatory glycans compared with men, but around menopause there’s a rapid shift toward a more inflammatory glycan profile,” explained Dr. Mohamed Abdel-Mohsen, the study’s senior author and an associate professor of medicine at Northwestern University.
While the researchers note that the exact interplay of shifting hormones and the age of initial viral infection requires further investigation, the data establishes that post-menopausal women experience a more pronounced drop in protective sugars, which tracks tightly with cognitive decline.
Proving the Chain Reaction: From Blood Patterns to Mice
To prove that the loss of these sugars was actually causing the memory issues—and wasn’t just a random byproduct of disease—the researchers moved from human blood samples to laboratory models. They utilized immune cells from patients alongside two specialized mouse models of HIV infection, one of which allowed for precise memory testing.
In the infected animal models, the researchers observed a clear, destructive domino effect:
-
Protective sialic acid sugars dropped sharply.
-
Inflammatory markers climbed.
-
Biological aging accelerated.
-
Cognitive performance and memory scores plummeted.
Because these changes occurred in lockstep, the team confirmed that sugar degradation was actively driving the subsequent inflammation and cognitive failure.
Repurposing Tamiflu to Block Sugar Destruction
The ultimate breakthrough came when the team looked into why the sugars were disappearing. They identified that the specific enzymes stripping sialic acid away from blood proteins are the exact same enzymes that influenza viruses use to break into human cells.
These enzymes are called sialidases (or neuraminidases). For decades, the primary defense against severe seasonal flu has been sialidase inhibitors—the most famous of which is Tamiflu.
Instead of using Tamiflu to block a viral enzyme, the researchers used it to block the body’s own overactive enzymes from destroying its protective sugars.
In the laboratory models, Tamiflu alone was not quite strong enough to halt the cognitive decline. However, when researchers paired Tamiflu with an experimental sialidase-inhibiting compound, the combination successfully preserved the protective sugars, quieted brain inflammation, slowed biological aging, and protected the animals’ memory.
“That’s really what’s novel,” noted Dr. Alan Winston, a professor of HIV medicine at Imperial College London who was not involved in the research. “The evidence so far runs through mice and a few hundred blood samples, so the road ahead is long. But there is now a clear target to aim at, and drugs already on pharmacy shelves to aim with.”
Demystifying Historical Tamiflu Concerns
When considering Tamiflu for long-term brain health, some medical professionals point to historical reports of rare neuropsychiatric side effects, such as delirium or hallucinations, which were occasionally observed in children taking the medication during flu outbreaks.
However, recent extensive epidemiological studies have largely re-evaluated these claims. Data from institutions like the Vanderbilt University Medical Center have shown that these neuropsychiatric events are typically caused by the high fever and severe inflammatory response of the influenza virus itself—not the medication. When safety profiles are evaluated outside active influenza infections, the drug class displays an established safety record.
Study Limitations and Caveats
While the study’s implications are profound, independent experts urge health-conscious consumers not to seek out off-label flu prescriptions for memory health just yet. Several critical barriers must be overcome before this research translates to human clinical therapies:
-
Preclinical Status: The successful reversal of memory decline was demonstrated in mice, not humans. Animal biology does not always mirror human clinical outcomes.
-
Small Human Sample Size: The initial discovery linking sugar loss to cognitive decline was based on blood samples from just over 100 human participants, limiting the statistical power needed to detect wider demographic variables.
-
The Combination Dependency: Tamiflu required a partnership with an unapproved, experimental compound to achieve brain protection. Tamiflu on its own, at standard flu dosages, is currently insufficient for this purpose.
-
Duration and Dosage Risks: Tamiflu is traditionally prescribed as a short 5-day course. Protecting the brain from chronic aging would likely require long-term use, an exposure length that has not yet been thoroughly vetted for safety or side effects.
The Road Ahead: Diagnostic Blood Tests and Optimization
Dr. Abdel-Mohsen’s team is currently advancing their research on two parallel tracks. First, they are performing additional preclinical work to optimize the pharmaceutical combination, aiming to create next-generation sialidase inhibitors tailored specifically for chronic, long-term use.
Second, they are working to develop simplified blood biomarker tests. If successful, a simple blood test measuring glycan degradation could allow clinicians to flag individuals at high risk for cognitive decline years before the first symptoms of memory loss appear.
While the study focused on people living with HIV, the mechanism of glycan degradation driving chronic inflammation is a universal feature of human biology. If future human clinical trials validate these findings, targeting sugar loss could offer a scalable, accessible pathway to protect memory and preserve brain health for an aging global population.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.earth.com/news/common-flu-drug-tamiflu-may-also-protect-the-brain-in-a-way-doctors-never-expected/
